SSShuji Suehiro

Shuji Suehiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuji Suehiro has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Case of Breast Carcinoma in an 86-year-old Woman Treated with Fulvestrant

    by Shuji Suehiro, Takafumi Hashimoto, Mirei Kamei, Atsushi Osoegawa, Michiyo Miyawaki, Kenji Sugio

    症例は86歳,女性.左乳房の変形,ひきつれを主訴に当院を受診し,左乳癌,cT2N0M0 stage IIA,ER:3b,PgR:2,HER2:1+と診断された.高齢のため侵襲的な治療は希望されず,ホルモン療法を開始した.アナストロゾール投与開始3カ月後,腫瘍の一時的な縮小を認めたが,投与7カ月目の検査で再増大を認め,フルベストラント(FUL)に変更した.治療開始後,腫瘍は増大せず(SD),以後1年間SDを継続した.乳癌診療ガイドラインによると,高齢乳癌症例に対しても非高齢者と同様に手術療法が標準となっている.しかし,高齢・併存疾患・死生観などを理由として手術の同意が得られない患者は一定数存在する.われわれは手術の同意が得られない高齢乳癌患者に対してフルベストラントを使用し,長期のSDを維持した症例を経験したので報告する.

  • Open Access

    The clinical manifestations and treatment of male breast cancer: a report of three cases

    by Shuji Suehiro, Miyuki Abe, Yohei Takumi, Takafumi Hashimoto, Mirei Kamei, Atsushi Osoegawa, Michiyo Miyawaki, Kenji Sugio

    Male breast cancer is an extremely rare malignancy. We treated three male breast cancer patients. All three patients showed clinical N0 and received sentinel lymph node biopsy. Because the sentinel lymph node was positive for metastasis in one patient, a total mastectomy with axillary lymph node dissection was performed. The other two patients were negative for sentinel lymph node metastasis, and a simple mastectomy was performed. Two of the patients were postoperatively treated with tamoxifen; another patient was treated with adjuvant chemotherapy using taxotere and cyclophosphamide before tamoxifen. There was no recurrence in any of the three patients during an average follow-up period of 56.7 months (range 11.8–80.3). A sentinel lymph node biopsy is recommended for node staging in both male and female breast cancer patients as it is associated with a lower incidence of complications.


  • Open Access

    Adenomyoepithelioma of the breast coexisting with ductal carcinoma in situ: a case report and review of the literature

    by Mirei Kamei, Tsutomu Daa, Michiyo Miyawaki, Shuji Suehiro, Kenji Sugio

    We herein report a case of adenomyoepithelioma (AME) of the breast with ductal carcinoma in situ (DCIS) involving a 71-year-old Japanese woman. She presented with bloody discharge from the left nipple. Mammography and ultrasonography showed a well-defined polygonal tumor. Fine-needle aspiration cytology of the mass and stamp cytology of the bloody nipple discharge showed malignancy. Mastectomy and a sentinel lymph node biopsy were performed. The final diagnosis was AME of the breast with DCIS. There are no reports of AME of the breast presenting with bloody nipple discharge; upon a diagnosis of AME of the breast with bloody nipple discharge, the possibility of the coexistence of breast cancer should thus be considered when encountering such cases.


    • 1 September 2012
      • p. 158-61

    [Bmi-1 expression in breast cancer].

    by Shin-Ichi Yamashita, Mirei Kamei, Shuji Suehiro

    • 1 November 2010
      • Vol. 30  (11) , 4779-83

    HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer.

    by Mirei Kamei, Shin-Ichi Yamashita, Keita Tokuishi, Takafumi Hashioto, Toshihiko Moroga, Shuji Suehiro, Kiyoshi Ono, Michiyo Miyawaki, Shinsuke Takeno, Satoshi Yamamoto, et al.

    This study investigated the potential of HE4 to predict disease-free survival for patients with breast cancer. One hundred and twenty-nine patients with breast cancer underwent surgery from January 2004 to September 2009. Immunohistochemical analysis (IHC) and RT-PCR were used to determine the expression of HE4 which was compared with the clinicopathological factors or prognosis. A total of 71 of 129 cases (55%) were HE4 positive and two cell lines expressed HE4 protein and mRNA. No correlation was found between HE4 expression by IHC and clinicopathological factors; however, lymph node involvement was closely associated with HE4 expression. Five-year disease-free survival in the HE4-positive group (58.6%) was significantly worse than that in the negative group (85.6%, p=0.04). These data showed that HE4 expression is associated with lymph node involvement and is a possible predictive factor of breast cancer recurrence.